- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of July 15
The Center for Biosimilars® recaps the top stories for the week of July 15, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 15, 2019.
Number 5: Coherus BioSciences says that, 6 months after launching its biosimilar pegfilgrastim, it has produced more than 400,000 syringes of the product.
Number 4: A rheumatology practice says that using a value-based pathway for rheumatoid arthritis has led to increased biosimilar use.
Number 3: Recent research shows that the Bipartisan Budget Act resulted in a decrease in out-of-pocket spending for biosimilars, but out-of-pocket spending on specialty generics has risen.
Number 2: According to the Congressional Budget Office, enacting the Lower Health Care Costs Act would reduce the deficit by more than 7 billion dollars by 2029.
Number 1: Celltrion announced that it is launching its first clinical trial of biosimilar CT-P39 referencing Xolair. The company plans to commercialize the biosimilar in 2022.
Finally, last week, our e-newsletter asked whether you think that shifting away from buy-and-bill practices for oncology drugs would help reduce costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
